Cue Biopharma Inc - ESG Rating & Company Profile powered by AI
The webpage contains a zero-cost E,S&G assessment covering Cue Biopharma Inc. This Sustainability rating for Cue Biopharma Inc indicates its reporting of the United Nations SDGs. Browse to the bottom of the webpage for potential risks for Cue Biopharma Inc based on sector, geography and size.
Cue Biopharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.5; made up of an environmental score of 4.0, social score of 8.0 and governance score of 1.6.
4.5
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 852 | Vaccibody AS | 4.6 | High |
| 852 | argenx SE | 4.6 | High |
| 868 | Cue Biopharma Inc | 4.5 | High |
| 868 | CARsgen Therapeutics Holdings Ltd | 4.5 | High |
| 868 | Boiron SA | 4.5 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Cue Biopharma Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Cue Biopharma Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Cue Biopharma Inc report the average age of the workforce?
Sign up for free to unlockDoes Cue Biopharma Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Cue Biopharma Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Cue Biopharma Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Cue Biopharma Inc offer flexible work?
Sign up for free to unlockDoes Cue Biopharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Cue Biopharma Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Cue Biopharma Inc conduct supply chain audits?
Sign up for free to unlockDoes Cue Biopharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Cue Biopharma Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Cue Biopharma Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Cue Biopharma Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Cue Biopharma Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Cue Biopharma Inc disclose water use targets?
Sign up for free to unlockDoes Cue Biopharma Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Cue Biopharma Inc have a product recall in the last two years?
Sign up for free to unlockDoes Cue Biopharma Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Cue Biopharma Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Cue Biopharma Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Cue Biopharma Inc disclose parental leave metrics?
Sign up for free to unlockDoes Cue Biopharma Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Cue Biopharma Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Cue Biopharma Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Cue Biopharma Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Cue Biopharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Cue Biopharma Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Cue Biopharma Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Cue Biopharma Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Cue Biopharma Inc disclose its waste policy?
Sign up for free to unlockDoes Cue Biopharma Inc report according to TCFD requirements?
Sign up for free to unlockDoes Cue Biopharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Cue Biopharma Inc disclose energy use targets?
Sign up for free to unlockDoes Cue Biopharma Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Cue Biopharma Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Cue Biopharma Inc
These potential risks are based on the size, segment and geographies of the company.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.